$0.69
0.77% yesterday
Nasdaq, Jul 14, 10:04 pm CET
ISIN
US04545L1070
Symbol
ASRT
Sector
Industry

Assertio Therapeutics, Inc. Stock price

$0.69
+0.04 5.49% 1M
-0.11 13.93% 6M
-0.19 21.28% YTD
-0.85 55.47% 1Y
-2.11 75.51% 3Y
-2.66 79.53% 5Y
-122.55 99.44% 10Y
-16.99 96.12% 20Y
Nasdaq, Closing price Mon, Jul 14 2025
-0.01 0.77%
ISIN
US04545L1070
Symbol
ASRT
Sector
Industry

Key metrics

Basic
Market capitalization
$66.2m
Enterprise Value
$17.8m
Net debt
positive
Cash
$87.3m
Shares outstanding
95.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 0.6
EV/Sales
0.2 | 0.2
EV/FCF
2.8
P/B
0.6
Financial Health
Equity Ratio
42.5%
Return on Equity
-17.8%
ROCE
-17.7%
ROIC
-15.1%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$119.0m | $116.0m
EBITDA
$1.8m | $10.7m
EBIT
$-27.9m | $-16.0m
Net Income
$-30.6m | $-30.9m
Free Cash Flow
$6.4m
Growth (TTM | estimate)
Revenue
-16.2% | -7.2%
EBITDA
-93.2% | 51.3%
EBIT
-1,876.3% | 14.6%
Net Income
90.8% | -43.1%
Free Cash Flow
-81.0%
Margin (TTM | estimate)
Gross
69.9%
EBITDA
1.5% | 9.2%
EBIT
-23.4%
Net
-25.7% | -26.6%
Free Cash Flow
5.4%
More
EPS
$-0.3
FCF per Share
$0.1
Short interest
6.1%
Employees
53
Rev per Employee
$2.4m
Show more

Is Assertio Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Assertio Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Assertio Therapeutics, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Assertio Therapeutics, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Assertio Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
119 119
16% 16%
100%
- Direct Costs 36 36
9% 9%
30%
83 83
24% 24%
70%
- Selling and Administrative Expenses 78 78
2% 2%
66%
- Research and Development Expense 3.53 3.53
1% 1%
3%
1.78 1.78
93% 93%
1%
- Depreciation and Amortization 30 30
8% 8%
25%
EBIT (Operating Income) EBIT -28 -28
1,876% 1,876%
-23%
Net Profit -31 -31
91% 91%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Assertio Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Assertio Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners Healthcare Company Showcase, taking place Wednesday, May 21, 2025.
Neutral
Seeking Alpha
2 months ago
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Matt Kreps - Investor Relations Brendan O'Grady - Chief Executive Officer Ajay Patel - Chief Financial Officer. Conference Call Participants Thomas Flaten - Lake Street Naz Rahman - Maxim Group Ram Selvaraju - H.C.
Neutral
GlobeNewsWire
2 months ago
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook
More Assertio Therapeutics, Inc. News

Company Profile

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Head office United States
CEO Brendan O'Grady
Employees 53
Founded 1995
Website www.assertiotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today